Pharmicell Co., Ltd.

KSE 005690.KS

Pharmicell Co., Ltd. EBIT Margin for the year ending December 31, 2023: 9.96%

Pharmicell Co., Ltd. EBIT Margin is 9.96% for the year ending December 31, 2023, a -10.76% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Pharmicell Co., Ltd. EBIT Margin for the year ending December 31, 2022 was 11.16%, a -49.00% change year over year.
Pharmicell Co., Ltd. EBIT Margin for the year ending December 31, 2021 was 21.88%, a 55.05% change year over year.
Pharmicell Co., Ltd. EBIT Margin for the year ending December 31, 2020 was 14.11%, a 80.12% change year over year.
Pharmicell Co., Ltd. EBIT Margin for the year ending December 31, 2019 was 7.83%, a 117.59% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KSE: 005690.KS

Pharmicell Co., Ltd.

CEO	Mr. Hyun-Soo Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Ssangbong Building
Employees	136
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Composite Materials Non-Alcoholic Beverages Petrochemicals Pharmaceuticals Plastics

Description

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years